Urinary Incontinence in Women Which treatments …...Objective •To review current epidemiology and...
Transcript of Urinary Incontinence in Women Which treatments …...Objective •To review current epidemiology and...
Urinary Incontinence in Women
Which treatments hold water?
Lieschen H. Quiroz, M.D.Associate Professor & Section Chief
Fellowship Director
1
Objective• To review current epidemiology and
clinical presentation of urinary
incontinence
• To review the basic evaluation for
patients
• To learn of surgical and nonsurgical
options for management
2
3
• Pelvic floor disorders (PFDs):
– Urinary incontinence (UI)
– Fecal incontinence (FI)
– Pelvic organ prolapse (POP)
• OB/GYN Subspecialty:
– Urogynecology
– Female Pelvic Medicine & Reconstructive Surgery (FPMRS)
Pelvic Floor Disorders
Incontinence: a common problem
Common and undertreated
Nearly 50% of adult women
experience incontinence
and 25-61% seek care
Reluctance may be from
embarrassment, lack of
knowledge of treatment and
fear of surgery
1-4
Impact on Health Quality of life- depression, work impairment, social
isolation
Sexual dysfunction-
Morbidity- increase mortality and healthcare costs
Increase caregiver burden- not able to perform other
ADLs
5
Shaw, C et al.. Fam prac 2001; 18:48-52.
Cumulative Lifetime Risk
0%
5%
10%
15%
20%
20 30 40 50 60 70 80
Cum
ula
tive incid
ence (
%)
Age (years)
Either SUI POP Either: 20.2%
(95%CI: 19.2, 21.2)
SUI: 14.5%
(95%CI: 13.4, 15.5)
POP: 13.7%
(95%CI: 12.6, 14.8)
Wu et al. Obstet Gynecol, 2014. PMID: 24807341.
Lifetime Risk of Surgery (SUI or POP)
Wu et al. Obstet Gynecol, 2014. PMID: 24807341.
0%
5%
10%
15%
20%
20 30 40 50 60 70 80
Cum
ula
tive incid
ence (
%)
Age (years)
80 yrs: 20.2%
1 in 5 women will undergo
surgery for stress incontinence
or prolapse by the age of 80
8
Urinary Incontinence
A symptom
A sign
A condition
9
Definition: Urinary incontinence
- Stress Urinary Incontinence (SUI)- the complaint of
involuntary leakage on effort on exertion, or on sneezing or coughing
- Urge Incontinence (UUI) - the complaint of involuntary
leakage accompanied by or immediately preceded by urgency
- Mixed Incontinence- the complaint of involuntary leakage
associate with urgency an also with exertion, effort, sneezing or
coughing.
10
Abrams et al,. Am J Obstet Gynecol. 2002 Jul;187(1):116-26.
Screening
First step is screening patients for symptoms
11
Brown J.S. et al: The sensitivity and specificity of a simple test to distinguish between urge
and stress urinary incontinence. Ann Intern Med 144. (10): 715-723.2006
Differential Diagnosis
GU etiology Non GU etiology
Filling/storage Functional
-SUI
-Overactive bladder
-Mixed incontinence
-Overflow incontinence
Neurologic
Cognitive
Environmental
Pharmacologic
Fistula Metabolic
-Vesical/ureteral/urethral
Congenital
-Ectopic ureter
12
From: Walters, MD. Description and classification of LUT Dysfunction and POP. En:
Walters MD Karram MM: Urogynecology and Reconstructive Surgery
Medical History
DIAPPERS: Reversible Causes of Incontinence
D elirium or confusion
I nfection, UTI
A trophic genital tract changes (vaginitis, urethritis)
P sychologic
P harmaceutical agents
E xcess urine production
R estricted mobility
S tool impaction
13
Conditions Causing Acute Urinary Incontinence
Delirium or confusion
Restricted mobility
Drugs
Urinary retention
Urinary Infection
Urethritis
Fecal impaction
Spinal cord compression
Polyuria
14
Office Evaluation of Female UI
History Gynecologic
Urologic
Neurologic
General Medical
Drugs
15
Office Evaluation of Female UI
History
Urologic symptoms SUI
UUI
Urgency/frequency
Number of voids in the day/ or after going to bed
Bedwetting
Dysuria
Difficulty voiding
Post-void fullness
Post-void dribbling
Hematuria
16
Drugs that May Affect Lower Urinary Tract
Class of Drugs Side Effect Impact on LUT
Psychotropic agents
Antidepressants
Antipsychotics
Sedatives/hypnotics
Alcohol
Caffeine
Diuretics
Narcotics
Ace Inhibitors
Calcium channel blockers
Anticholinergic
Alpha-adrenergic agonists
Alpha-adrenergic blockers
Beta-adrenergic agonists
Anticholinergic, sedation
Anticholinergic, sedation
Sedation, muscle relaxation
Sedation, impaired mobility
Sedation, confusion
Cough
Increase Urethral Tone
Decrease Urethral Tone
Increase Urethral Tone
Urinary retention
Urinary retention
Urinary retention
Diuresis, frequency
Urgency, frequency
Polyuria, urgency, frequency
Urinary retention, fecal impaction
Aggravate preexisting SUI
Urinary retention, overflow
incontinence
Urinary retention, overflow
incontinence
Urinary retention
Stress incontinence
Urinary retention
17
Bladder Diary
18http://www.augs.org/Portals/0/Voiding_Diary.pdf
Diagnostic Evaluation
Neurologic Sensation S2-S4 Pelvic reflexes
Pelvic Support (POP-Q) Muscle strength Q-tip PVR or US for residual urine Cough Stress Test
Postvoid residual testing h/o pelvic surgery, DM, other neurologic conditions. Elevated if >150cc on 2 occasions
Evaluate for UTI- can mimic either SUI or UUI
19
Physical Examinaton for POP
Evaluate all anatomic sites for possible defects
Urethra
Bladder
Cervix or apex
Cul-de-sac
Rectum
Perineal body
20
Pelvic Muscle Strength Testing Physical Exam
21
Grade Examination
0 No visualized or palpable contraction
1 Flicker
2 Weak pelvic contraction
3 Moderate Contraction with an element of lift
4 Good contraction with lift and holding power
5 Strong squeeze with good lift gripping examining
hand
Vasavada, S., Apelle, R. ( 2005) Female Urology, Urogynecology and Voiding Dysfunction. Marcel Dekker, p.134.
Urethrovesicle Junction Mobility
22
▪Q-tip test
Office Evaluation of Female Urinary
Laboratory Tests
Urinalysis
Urine Culture
Other: BUN/Cr, Cytology
23
Simple CMG
24
Clinic Note for a simple CMG Timed, measured void
Urinalysis
PVR volume with catheter or US
First sensation to bladder filling
Bladder capacity
Provocation during filling to elicit OAB
Full bladder cough stress test
25
Physical Exam: Cough Stress Test
26
27
Acute Condition?
Urinary Incontinence in WomenHistory and physical examination
Post-void residual urine measurement
YesTreat
Complex Condition?Consult w/ Urogynecologist
or Urologist
No
No
Yes
Sx of SUI? Yes
Urgency,
Frequency, Enuresis?Presume Mixed UIPresume DO
Stress Test? +
No
Urgency,
Frequency, Enuresis?No
Presume SUI
Yes
YesProminent
SUI Sx TX
Nonsurgical Treatment: SUI
Behavioral Management of fluid intake
Weight reduction
Pelvic floor exercises for SUI http://kidney.niddk.nih.gov/Kudiseases/pubs/pdf/exercise_ez.pdf
Recommended regimen includes 3 sets of 8-12 slow velocity, maximum intensity PFE sustained for 8-10 sec
3-4 times/week for 15-20 weeks.
Patients who fail to improve with this approach should be referred to a specialist
28
Physiotherapy for Stress Incontinence Trained physical therapist
Biofeedback
Electrical stimulation
Goal
Rehabilitate and strengthen pelvic floor muscles
Outcomes
Improvement: 50-75%
May take 2-3 months to see improvement
Risks: none!
29
Nonsurgical Treatment: SUI Pessary
Silicone devices that can provide support to pelvic organs and treat SUI by increasing urethral resistance
~50% of women who use a pessary for SUI continue to use it at 2 years
Discontinue if: irritation, discharge, odor, ulceration, bleeding
Low cost, easy to use, rare side effects
30
Nguyen J.N., et al. Pessary treatment of pelvic relaxation: factors affecting successful
fitting and continued use. J Wound Ostomy Continence Nurs 32. (4): 255-261.2005
Modern Pessaries
31
Surgical Management
Several conditions must be met
Correct diagnosis
Trial of conservative therapy
Acceptable surgical candidate
Does not desire fertility (+/-)
32
Surgical Management Patients who fail pelvic floor exercises and devices
should be referred to a specialist to consider further
options
Mainstay surgeries include:
Minimally invasive midurethral sling-retropubic or
transobturator approach
Retropubic urethropexy (Burch procedure)
Transurethral bulking agents
33
34
NEW Developments OTC Option for SUI
35
Urge Incontinence (UUI) - the complaint of
involuntary leakage accompanied by or immediately
preceded by urgency
36
Treatment UUI
Behavioral
Fluid management
Timed voiding
Pelvic floor exercises
Biofeedback
Shown to be as effective as anticholinergic medication in treatment of UUI in older women
37
Burgio K.L., et al: Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized
controlled trial. JAMA 280. (23): 1995-2000.1998
Physiotherapy for Urge Incontinence
Behavioral
modification
Retraining drills
Fluid management
Decrease bladder
irritants
“Freeze and squeeze”
Biofeedback
Electrical stimulation
38
Anticholinergic agents Belladona first introduced in 1936
Atropine: first anticholinergic introduced. Prominent
sdx profile
Severe side effects led
to development
synthetic analogs
39
Oxybutinin Tertiary amine, Nonselective Antagonist
“Mixed” action:
anticholinergic
antispasmodic
local anesthetic
antihistaminic effects
PO (IR and CR), intravesical, PR, and
transdermal
2.5- 5 mg tid or qid
40
Oxybutynin – transdermal(Oxytrol)
Bypasses the first-pass GI and hepatic metabolism Patch applied 2x/wk Applied to dry, intact skin on the abdomen, hip or
buttock New application site with each new system Avoid re-application to the same site within 7 daysIn vivo delivery rate of 3.9 mg per day After removal, plasma concentrations of oxybutynin
and N-desethyloxybytynin decline with a half-life of 7 – 8 hours
Plasma concentration declines within 1 – 2 hrs after removal
Adhesion: 0.4% completely detached; 0.7% partially detached
41
Oxybutynin – TD (Oxytrol) Severe application site reactions 5 %
10% resulting in discontinuation – most secondary to
application site reaction
None d/c’ed due to dry mouth
Several studies comparing to placebo and other
anticholinergics (eg. Long acting Tolterodine) prove it
effective in treatment UI sx.
42
Dmochowski RR, et al; Transdermal Oxybutynin Study Group. Comparative efficacy and safety of
transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge
and mixed urinary incontinence.
Urology. 2003 Aug;62(2):237-42.
Dmochowski RR, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder:
combined results of two randomized clinical trials.World J Urol. 2005 Sep;23(4):263-70. Epub 2005
Nov 8.
Oxybutynin – TD (Gelnique)
Transdermal delivery system (Gel 10%)
Average daily dose of 1 gram
(concentration 100mg/mg)
serum concentration 5 ng/ml
Skin reaction 5.4% (PI)
3.9% trial discontinuation
Tolteridine (Detrol) Nonselective Antimuscarinic
Fast absorption
IR half-life 2-3 hrs
ER –Detrol LA- 2 mg, 4 mg
44
Solifenacin (Vesicare) Potent M3 Receptor antagonist, selective M3>M2
Half life ~50 hours (range 45-68)
5 mg, 10 mg; once a day dosing
Metabolized (primarily by CYP3A4) in the liver
45
Darifenacin (Enablex) Potent muscarinic M3 selective receptor antagonist
7.5 mg, 15 mg once daily
Metabolized CYP450 3A4 and 2D6: caution with
TCA, flucanide, thioridazine & any CYP inhibitor
46
Trospium Quaternary amine compound
Higher specificity to M2 M3
Half life 12-18 hrs; 20 mg bid
Excreted unchanged; no CYP450 interaction;
renal excretion careful w/ digoxin, procainamide, morphine, metformin
Low (5%) biological activity
Does not cross blood brain barrier (less lipophilic) -> no negative cognitive effects
47
Fesoteradine (Toviaz) Approved by FDA in October 2008
Nonhepatically metabolized to 5-HMT, which is the
active metabolite of tolterodine.
Phase III trial demonstrated clinical improvement in
OAB sx for patients treated with 4 mg and 8 mg.
Most common Sdx: Dry mouth
48
Nitti et al. J Urol 2007; 178; 2488.
Mirabegron (Mybetriq) β3-Adrenoceptor Agonist
Once daily dosing (25mg-50mg)
Cui et al
Compared with placebo, ↓ # incontinent episodes
/24hrs by -0.44 (95% CI -0.59, -0.29)
Less dry mouth than anti-cholinergics
treatment-emergent HTN developed in 8.4 % on placebo,
13.6 % on mirabegron 25 mg, and 10 % on mirabegron
50 mg
Cui Y, Zong H, Yang C, et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-
analysis of phase III trials. Int Urol Nephrol 2014; 46:275.
Wagg A, Cardozo L, Nitti VW, et al. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the
treatment of symptoms of overactive bladder in older patients. Age Ageing 2014; 43:666.
What if they fail medications, what do you do in your practice?What are the options?
Normal bladder capacity:
▪ Botox
▪ PTNS (Peripheral tibial nerve stimulation)
▪ Interstim (Sacral nerve stimulation)
BotulinumToxin About 70%
improvement
in symptoms
Risk UTI, retention
Repeated q4-6 mo’s
51
Sacral Neuromodulation InterStim®
Successful treatment of:
Urgency-frequency 64%
Urge incontinence 76%
Urinary retention 61%
Complications
Pain at implant/electrode site
Infection
Lead migration
InterStimInterStim®® TherapyTherapySacral Nerve Stimulation for Urinary Sacral Nerve Stimulation for Urinary
ControlControl
InterStimInterStim®® Test Stimulation Test Stimulation
ProcedureProcedure
◼◼ Simple outpatient procedure Simple outpatient procedure
◼◼ Done under local anestheticDone under local anesthetic
Implantation of Interstim® System
53
Summary PFD are common and costly in terms of health care
dollars and patient quality of life
Effective nonsurgical interventions exist for urinary incontinence
Primary care providers are ideal for screening for these disorders
Better understanding of prevention methods of PFD in women of all ages
54
Thank [email protected]
55